In April 2026, the Cochrane Collaboration, widely regarded as the gold standard for evidence review in medicine, published a review concluding that anti-amyloid drugs for Alzheimer's disease show little to no clinically meaningful benefit. The finding made headlines and understandably alarmed families whose loved ones are currently on or considering treatment with lecanemab or donanemab, the two approved anti-amyloid drugs on the market.
The review is genuinely more complicated than the headlines suggest, and other respected researchers and regulators have pushed back on how it was framed. Here is a balanced look at what the review actually found, why the disagreement exists, and what it should mean for a family weighing treatment right now.
Averaging failed drugs together with the two that actually showed clinical benefit dilutes a real, if modest, effect into statistical noise.
What the Cochrane Review Actually Found
Researchers pooled data from 17 clinical trials involving more than 20,000 participants with mild cognitive impairment or mild dementia due to Alzheimer's disease, evaluating a range of anti-amyloid drugs. The pooled analysis concluded that these drugs make little to no meaningful difference in functional ability, and the review also raised safety concerns around ARIA, the brain swelling or bleeding risk associated with this drug class.
What Went Into the Pooled Analysis
Why Some Experts Are Pushing Back
The core criticism is about how the trials were pooled. Of the drugs included in the review, most either failed in clinical trials or were never brought to market. Only two, lecanemab and donanemab, are currently FDA-approved and available to patients. Critics, including researchers at the UK Dementia Research Institute and the Alzheimer's Society, argue that averaging failed drugs together with the two that actually showed clinical benefit dilutes a real, if modest, effect into statistical noise. Regulators including the UK's Medicines and Healthcare products Regulatory Agency reviewed lecanemab and donanemab separately and found a small but meaningful benefit for early-stage Alzheimer's disease.
Just How Small Is "Small"? Putting the Numbers in Context
Even among defenders of these drugs, the actual numbers are modest. In the pivotal trial for lecanemab, the drug slowed decline on an 18-point cognitive and functional scale by 0.45 points over 18 months compared to placebo. Donanemab slowed decline by 0.67 points on a similar scale in its own pivotal trial. Eisai, lecanemab's manufacturer, frames this as a 27 percent slowing of disease progression. Some independent researchers frame the same number differently, noting that 0.45 points represents about 2.5 percent of the full scale range. Both framings are technically accurate, and the honest takeaway is that the effect is real but small, not a cure and not a dramatic turnaround.
Worth noting: this article is general information, not medical advice. Any decision about starting, continuing, or stopping treatment should be made with the prescribing neurologist.
What Longer-Term Data Adds to the Picture
Part of the ongoing debate involves what happens after the initial 18-month trial period ends. Some researchers point to emerging extension data suggesting that, after roughly three years, there is little measurable difference between patients who started treatment early and those whose treatment was delayed, which raises a genuinely open question about whether these drugs meaningfully change the overall course of the disease or mainly provide a temporary, symptom-level benefit early on. Other researchers argue this comparison is complicated by real-world factors that a controlled trial does not fully capture. Neither side of this debate has fully settled the question, which is itself useful for families to understand rather than assuming the science here is more resolved than it actually is.
The Safety Side of the Conversation
Regardless of which side of this debate a researcher falls on, the ARIA risk, involving brain swelling or bleeding visible on imaging, is a consistent point of caution raised by both critics and supporters of anti-amyloid treatment. This is part of why ongoing MRI monitoring is required throughout treatment.
What This Actually Means for a Family Weighing Treatment
This review is not a reason to panic, and it is not a reason to assume there are no options at all. It is a reason to go into a treatment conversation with realistic expectations about how much benefit to expect and a clear understanding of the safety monitoring involved. It is also a good moment to remember that medication is only one part of a broader care picture. Structured, dementia-informed daily care, the kind covered in our article on California's updated dementia care standards for RCFEs, matters regardless of which medication path a family chooses. If your family is also looking at the newer at-home injection option for lecanemab, our article on that approval covers what it changes and what it does not.
Common Questions Families Ask
Does the Cochrane review mean lecanemab and donanemab do not work at all?
Not exactly. The pooled review found little meaningful benefit across all anti-amyloid drugs studied, most of which failed or were discontinued. Regulators who reviewed lecanemab and donanemab specifically found a small but meaningful benefit for those two approved drugs.
Quick Takeaway
The Cochrane review found little pooled benefit across anti-amyloid drugs, but experts note it mixed failed drugs with the two approved ones. The honest takeaway is a real but modest benefit for lecanemab and donanemab, worth discussing directly with a neurologist.
Why do different experts disagree about the same review?
The disagreement centers on methodology: whether it makes sense to pool 12 failed or discontinued drugs together with the two that are actually approved and available, which critics argue understates the real, if modest, benefit of lecanemab and donanemab specifically.
Should this review change a decision to start or continue anti-amyloid treatment?
Any decision about starting, continuing, or stopping treatment should be made with the prescribing neurologist, who can weigh this evidence alongside the individual patient's specific situation. Do not make treatment decisions based on a news article or review summary alone.
Do these drugs stop Alzheimer's disease from progressing?
No. Even the drugs with demonstrated benefit slow decline modestly rather than stopping or reversing it, and some longer-term data raises questions about how durable that effect actually is over several years.
Should a family read the original Cochrane review, or is a summary enough?
A summary from a reputable source is reasonable for a general understanding, but any decision about actual treatment should still go through the prescribing neurologist, who can weigh the full body of evidence alongside your specific situation rather than a single review in isolation.
This article is general information, not medical advice, and should not be used to make treatment decisions. Talk with the prescribing physician about what this evidence means for your family's specific situation. If you have questions about dementia-informed care at one of our homes, reach out through our Contact Us page or call (951) 900-4326. We are available Monday through Sunday, 8:00 AM to 8:00 PM.
Ask Us About Dementia-Informed Care
Quick takeaway: the Cochrane review found little pooled benefit across anti-amyloid drugs, but experts note it mixed failed drugs with the two approved ones. The honest takeaway is a real but modest benefit, worth discussing directly with a neurologist.
Talk to Our Team →